- A $ 5 million funding round led by Kizoo Technology Capital
- New capital to be used in production, to set up a clinical trial in transplantation and to expand the Cellvie pipeline in rejuvenation treatments
- The promising initial clinical data generated at Boston Children’s Hospital will be published in the Journal of Thoracic and Cardiovascular Surgery
Zurich / Switzerland and Houston / USA, 25 January 2021: Cellvie Inc. is closing down. Harvard University, a leader in mitochondrial transfer therapeutic (TMT), has launched a $ 5 million round to develop its product pipeline, including its first application in a regeneration.
Mitochondria are closely related to the origin of complex life, youth energy and aging population. They are the power centers in the cell, and they generate most of the cellular energy and act as critical communication nodes inside the cell. Mitochondrial dysfunction has been linked to a host of diseases, ranging from neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, heart attacks and strokes, to age-related degeneration.
“But treating mitochondria has proven to be a daunting challenge,” said Dr. James McCauley, founder of Cellvie and Associate Professor of Surgery at Children’s Hospital of Boston and Harvard Medical School, where he pioneered the therapeutic use of mitochondria. That is why we have resorted to introducing healthy and viable mitochondria into cells where these organelles are disrupted. To great effect. We can sustainably activate a failed energy metabolism in cells. ”
The potential of therapeutic mitochondrial transfer was recently demonstrated in a clinical investigation at Boston Children’s Hospital. Pediatric patients receiving heart and lung support after suffering cardiogenic shock received treatment to stimulate the heart muscle. 80% of these children experienced a heart muscle recovery, which compares with the 29% expected, as reported in an upcoming publication in the Journal of Thoracic and Cardiovascular Surgery.
“The implications of our findings are pioneering.” Dr. Alexander Schuyler, founder and CEO of cellvie, said, “We may have the opportunity to find a new treatment method.” “The investment will enable us to follow the platform on a large scale, including the first application in aging, The need to restore mitochondria is especially high.
To date, cellvie has mainly focused on ischemia and infusion injury (IRI), which is one of the leading causes of death in the world. IRI manifests itself when blood flow to a part of the body is cut off and then reappears. Known medical conditions include heart attacks, strokes, and organ transplants. Cellvie is pursuing an index in organ transplantation, first, the US Food and Drug Administration granted the FDA classification in 2020. Capital Syringe will be used for production, to expand the cellvie’s product pipeline and to prepare the IND’s submission for the clinical study in kidney transplantation.
“We were immediately drawn to the potential of the cellvie approach to emerge as a new class of drugs,” said Frank Schuyler, Managing Director at Kizoo Technology Capital. “With mitochondrial dysfunction having a common denominator of disease and aging alike, the ability of cellular cells to influence cell energy metabolism may pave the way for treating hitherto intractable human diseases.” Frank Schuyler will join the company’s board of directors.
About Cellvie Inc.
Founded in the USA and headquartered near Zurich, Switzerland, Cellvie is developing drugs from cells, tapping into the therapeutic potential of mitochondria. The company was founded by Drs McCauley, Schuyler, Dale Nido, and Faithi in 2018. Dr. McCauley pioneered the mitochondrial augmentation and replacement approach at Harvard Medical School, and the team has now embarked on rolling it out as a new treatment method in ischemia and reperfusion injury, aging and beyond. More information can be found at cellvita-science.com
KIZOO provides guidance, seed funding and early stage financing with a focus on biotechnology for regeneration. As entrepreneurs, venture capitalists, and mentors in both high-growth biotechnology and biotechnology companies for many years with multiple exits and tremendous value created for founders, Kizoo is now taking this experience into the emerging biotech field of innovation. We see it as a young industry that will eventually overtake today’s largest technology market.
As part of the Forever Healthy Group, Kizoo directly supports the creation of startups that transform the search for the root causes of aging into treatments and services for human use. Investments include FoxBio, Turn.bio, AgeX, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, and ohers.
Other Forever Healthy initiatives include evaluating new regenerating therapies, evidence-based treatment of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference.
More information can be found at http: // www.
Dr. Alexander Schuyler
Phone: + 41-44 591 89 21
E-mail: [email protected]